

Dear Grant Team, Please find attached the CCV of PI and Co-PI as one-PDF

1. Dr. Daniel Adam BREADNER, MD (PI)
2. Dr. Saqib Raza KHAN, MD (Co-PI)

Thank You.

Date Submitted: 2024-09-04 13:34:35

Confirmation Number: 1812960

Template: CIHR Biosketch

Dr. Daniel Adam Breadner

Correspondence language: English

Sex: Male

Date of Birth: 8/30

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

A3-913, LRCP, Medical Oncology
800 Commissioners Road East
London Ontario N6A5W9
Canada

Telephone

Work (*) 1-519-6858500 extension: 58640

Email

Work (*) Daniel.breadner@lhsc.on.ca

Website

Community <https://www.lhsc.on.ca/london-regional-cancer-program/division-of-medical-oncology>



Protected when completed

Dr. Daniel Breadner

Degrees

2010/8 - 2014/5	Doctorate, MD, University of Western Ontario Degree Status: Completed
2006/9 - 2008/8	Master's Thesis, M.Sc., University of Western Ontario Degree Status: Completed
2001/9 - 2005/4	Bachelor's, B.Sc, University of Western Ontario Degree Status: Completed

Credentials

2020/6	Assistant Professor, University of Western Ontario
--------	--

Recognitions

2020/6 - 2020/6	Top Abstract and Oral Presentation Canadian Association of Medical Oncologists
2020/5 - 2020/5	Novartis Oncology Young Canadian Investigator Awards - Research Award for Oncology Trainees Novartis
2019/9 - 2019/9	World Conference on Lung Cancer Early Career Travel Award International Association for the Study of Lung Cancer
2019/6 - 2019/6	Oncology Research and Educational Day Poster Award Schulich School of Medicine & Dentistry
2019/1 - 2019/1	Dr. Ed Brecevic Award for Compassionate Care Schulich School of Medicine & Dentistry

Employment

2020/6	Medical Oncologist Medical Oncology, London, Ontario, London Regional Cancer Program
2020/6	Assistant Professor Oncology, Schulich School of Medicine and Dentistry, London, Ontario, University of Western Ontario
2008/9 - 2010/7	Laboratory manager London Regional Cancer Program

Affiliations

The primary affiliation is denoted by (*)

(*) 2020/5 Assistant Professor, Oncology, University of Western Ontario

Research Funding History

Awarded [n=13]

2022/9 - 2029/1 Collaborator	NEEDS Trial - Randomized study of CROSS protocol versus dCRT in esophageal squamous cell carcinoma Funding Sources: Canadian Clinical Trials Group Gastrointestinal Disease Site Team Total Funding - 1,813,050 Funding Competitive?: Yes
2021/7 - 2027/7 Co-investigator	Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial Funding Sources: Canadian Institutes of Health Research (CIHR) Spring Project Competition Total Funding - 1,426,724 Funding Competitive?: Yes
2022/11 - 2025/7 Principal Investigator	Detection of Circulating Tumor DNA after Stereotactic ablative body radiotherapy (SABR) in Patients with Unbiopsied Lung Tumors (SABR-DETECT) Funding Sources: Lawson Health Research Institute Internal Research Fund Total Funding - 19,800 Funding Competitive?: Yes Lung Cancer Canada Geoffrey Ogram Memorial Research Grant Total Funding - 25,000 Funding Competitive?: Yes London Health Sciences Centre Medical Oncology Research Fund Total Funding - 30,000 Funding Competitive?: Yes
2024/7 - 2025/6 Principal Investigator	A program to develop the capacity and capability to provide bispecific T-cell therapy to patients with solid tumors Funding Sources: London Health Sciences Centre Academic Realignment Initiative Award Total Funding - 67,500 Funding Competitive?: Yes
2020/1 - 2025/4 Co-applicant	OCELOT - Osimertinib then chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge Funding Sources: AstraZeneca Clinical Trial

	Total Funding - 4,000,000 Funding Competitive?: Yes
2021/12 - 2024/12 Principal Applicant	A pilot study to Assess the safety and feasibility of Neoadjuvant Stereotactic ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma (ANSR-PDAC) Funding Sources: Ontario Institute for Cancer Research Window of Opportunity Grant Total Funding - 247,900 Funding Competitive?: Yes
2021/10 - 2024/10 Principal Investigator	Modulation of the tumour immune microenvironment with neoadjuvant stereotactic ablative radiotherapy in pancreatic ductal adenocarcinoma (ANSR-PDAC) Funding Sources: Academic Medical Organization of Southwestern Ontario Opportunities Grant Total Funding - 130,000 Funding Competitive?: Yes
2021/2 - 2023/2 Principal Investigator	Prospective Study of Blood-based Biomarkers of Immunogenicity and Tissue Immune Profiling in Patients with Resectable Pancreatic Ductal Adenocarcinoma Treated with Stereotactic Ablative Radiotherapy Funding Sources: London Health Sciences Foundation London Health Sciences Foundation Total Funding - 60,000 Funding Competitive?: No
2022/1 - 2023/1 Co-investigator	Validation of a Machine Learning Algorithm to Predict Tumour Mutational Burden Based on an H&E Morphologic Signature and Prediction of Response to Immunotherapy in Squamous Lung Cancer Funding Sources: Ontario Institute for Cancer Research (OICR) Cancer Pathology Translational Research Grant Total Funding - 52,148 Funding Competitive?: Yes
2021/11 - 2021/11 Co-investigator	Modulation of the tumour immune microenvironment with neoadjuvant stereotactic ablative radiotherapy in pancreatic ductal adenocarcinoma (ANSR-PDAC) Funding Sources: London Health Sciences Foundation London Health Sciences Foundation Total Funding - 100,000 Funding Competitive?: No
2021/10 - 2021/10 Principal Investigator	TMB morphology signature as novel marker of response to immunotherapy in lung cancer Funding Sources: Schulich School of Medicine & Dentistry - Department of Oncology; Division of Medical Oncology Medical Oncology Research Fund Total Funding - 13,000 Funding Competitive?: Yes
2019/1 - 2021/1 Co-applicant	Circulating Tumour DNA in Lung cancer (CITaDeL): Optimizing sensitivity and clinical utility

Funding Sources:

Schulich School of Medicine & Dentistry - Department of Oncology; Division of Medical Oncology
 Medical Oncology Research Fund
 Total Funding - 25,000
 Funding Competitive?: Yes

2021/1 - 2021/1
 Co-investigator

TMB morphology signature as novel marker of response to immunotherapy in lung cancer

Funding Sources:

Schulich School of Medicine & Dentistry - Department of Oncology; Division of Medical Oncology
 Medical Oncology Research Fund
 Total Funding - 15,000
 Funding Competitive?: Yes

Publications

Journal Articles

1. Waugh E, Glinka J, Breadner D, Liu R, Tang E, Allen L, Welch S, Leslie K, Skaro A. (2024). Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer. *Annals of Hepatobiliary Pancreatic Surgery*. 28(2): 229-237.
Published
2. Verma S, Breadner D, Mittal A, Palma DA, Nayak R, Raphael J, Vincent M. (2024). An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. *Cancers*. 16(7): 1302.
Published
3. Verma S, Young S, Kennedy TAC, Carvalhana I, Black M, Baer K, Churchman E, Warner A, Allan AL, Izaguirre-Carbonell J, Dhani H, Louie AV, Palma DA, Breadner DA. (2024). Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT). *Clinical Lung Cancer*. 25(2): e87-e91.
Published
4. Strum S, Vincent M, Gipson M, McArthur E, Breadner D. (2024). Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management. *Oncotarget*. 15: 381-388.
Published
5. Chinnadurai A, Breadner D, Baloush Z, Lohmann AE, Black M, D'Souza D, Welch S. (2024). Adjuvant carboplatin and paclitaxel with "sandwich" method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single institution. *Journal of Gynecology Oncology*. 35(2): e16.
Published
6. Verma S, Grindrod N, Breadner D, Lock M. (2024). The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review. *Cancers (Basel)*. 16(9): 1776.
Published
7. Chinnadurai A, Strum S, Ghassemian A, Fortin D, Foster C, Breadner D. (2023). A Rare Association of Mixed Autoimmune Hemolytic Anemia with Gastric Carcinoma. *Case Reports in Oncology*. 16(1): 1209-1216.
Published

8. Verma S, Young S, Louie AV, Palma D, Breadner D. (2023). The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer. *Therapeutic Advances in Medical Oncology*. 15: 17588359231192399.
Published
9. Balta KY, Welch S, Vincent M, Breadner D. (2023). Near 5-year survival in metastatic pancreatic cancer patient with ROS1 rearrangement, HER2 amplification, and KRAS G12C mutation—a case report. *The Journal of Gastrointestinal Oncology*. 14(5): 2273-2278.
Published
10. Wang H, Breadner DA, Deng K, Niu J. (2023). CircRHOT1 restricts gastric cancer cell ferroptosis by epigenetically regulating GPX4. *Journal of Gastrointestinal Oncology*. 14(4): 1715-1725.
Published
11. Dammak S, Cecchini MJ, Breadner D, Ward AD. (2023). Using deep learning to predict tumor mutational burden from scans of Hematoxylin & Eosin (H&E)-stained multicenter slides of lung squamous cell carcinoma. *Journal of Medical Imaging (Bellingham)*. 10(1): 1285.
Published
12. Verma S, Breadner D, Raphael J. (2023). 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review. *Current Oncology*. 30(4): 4329-4350.
Published
13. Deluce J, Maj D, Verma S, Breadner D, Boldt G, Raphael J. (2023). Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: A Systematic Review and Meta-analysis. *Am J Clin Oncol*. 46(3): 87-93.
Published
14. Verma S, Vincent M, Breadner D. (2023). Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. *New England Journal of Medicine*. 389(16): 1534.
Published
15. Bhai P, Turowec J, Santos S, Kerkhof J, Pickard L, Foroutan A, Breadner D, Cecchini M, Levy MA, Stuart A, Welch S, Howlett C, Lin H, Sadikovic B. (2023). Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory. *Frontiers in Oncology*. 13: 1208244.
Published
16. Preti BTB, Sanatani MS, Breadner D, Lakkunarajah S, Scott C, Esmonde-White C, McArthur E, Rodrigues G, Chaudhary M, Mutsaers A, Sachdeva R, Vincent MD. (2023). Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer. *Current Oncology*. 30(8): 7713-7721.
Published
17. Zayed S, Louie AV, Breadner DA, Palma DA, Correa RJM. (2023). Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions. *Therapeutic Advances in Medical Oncology*. 15(0): 17588359231183668.
Published
18. Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Fumihito Yamaguchi, Daniel Breadner, Tatsuya Nagano, Fumihito Tanaka, Hatim Husain, Kai Li, and Baohui Han. (2022). The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study. *Translational Lung Cancer Research*. 11(5): 776-785.
Published
Refereed?: Yes, Open Access?: Yes

- [19.](#) Breadner DA, Vincent MD, Correa R, Black M, Warner A, Sanatani M, Bhat V, Morris C, Jones G, Allan A, Palma DA, Raphael J. (2022). Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study. *Lung Cancer*. 165: 145-151.
Published
- [20.](#) Lakkunarajah S, Breadner D, Zhang H, Spratlin JL, Mulder KE, Gill S, Sha A, Abadi S, Kong S, Cheung KS, Loree JM, Welch S. (2021). The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis. *Current Oncology*. 28(5): 4031-4041.
Published
- [21.](#) Preti BTB, Pencz A, Cowger JJM, Vincent MD, Breadner D. (2021). Skin Deep: A Fascinating Case Report of Immunotherapy-Triggered, Treatment-Refractory Autoimmune Lichen Planus and Keratoacanthoma. *Case Reports in Oncology*. 14: 1189-1193.
Published
- [22.](#) Zhang T, Sun B, Zhong C, Xu K, Wang Z, Hofman P, Nagano T, Legras A, Breadner D, Ricciuti B, Divisi D, Schmid RA, Peng RW, Yang H, Yao F. (2021). Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in *EGFR*-activating mutant lung adenocarcinoma. *Translational Lung Cancer Research*. 10(4): 1857-1872.
Published
- [23.](#) Lakkunarajah S, Breadner DA, Zhang H, Yamanaka E, Warner A, Welch S. (2021). The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis. *Current Oncology*. 28(5): 4031-4041.
Published
24. Breadner D, Blanchette P, Shanmuganathan S, Boldt RG, Raphael J. (2020). Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis. *Lung Cancer*. 144(June): 57 - 63.
Published
25. Breadner, D., Raphael, J. (2020). One Step Too Far in the Right Direction: The Society for Translational Medicine 2019 consensus on postoperative management of *EGFR*-mutant lung cancer. *Journal of Thoracic Diseases*. 12(9): 5046 - 5049.
Published
26. Fatehi Hassanabad, A., Chehade, R., Breadner, D., Raphael, J. (2020). Esophageal carcinoma: Towards targeted therapies. *Cellular Oncology*. 43: 195 - 209.
Published
27. Breadner D, Vincent MD, Jonker D, Cripps C, Klimo P, Biagi J, Lam W, O'Connell A, Whiston F, Stitt L, Welch S. (2018). Health related quality of life in older or frail patients with advanced colorectal cancer treated with dose reduced capecitabine. *Journal of Geriatric Oncology*. 9(6): 659 -664.
Published
- [28.](#) Mahler M, Teft W, Breadner D, Bukhari N, Kuruvilla S, Nichols A, Palma D, Kim R, Winquist E. (2018). The Effect of *MATE1* Polymorphisms on Cisplatin Efficacy in the Treatment of Head and Neck Cancer. *International Journal of Radiation Oncology*. 100(5): 1377-1378.
Published
- [29.](#) Surujballi J, Breadner D, Morris D, O'Connor A, Whiston F, Stitt L, Vincent MD. (2018). A Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*. 13(10): S498.
Published
30. Vincent, M.D., Breadner, D., Cripps, C., Jonker, D.J., Klimo, P., Biagi, J.J., Lam, W., O'Connell, A., Whiston, F., Stitt, L., Welch, S.A. (2017). Phase II trial of dose reduced capecitabine in elderly patients with advanced colorectal cancer. *Current Oncology*. 24(4): 261 - 268.
Published

31. Vincent, M.D., Breadner, D., Soulieres, D., Kerr, I.G., Sanatani, M., Kocha, W., Klimo, P., MacKenzie, M.J., O'Connell, A., Whiston, F., Malpage, A.S., Stitt, L., Welch, S.A. (2017). Phase II Trial of Capecitabine plus Erlotinib Versus Capecitabine Alone in Patients with Advanced Colorectal Cancer. *Future Oncology*. 13(9): 777 - 786.
Published

Conference Publications

1. Breadner D, Whiston F, Stitt L, Welch S. Impact of relative dose intensity and G-CSF use in the adjuvant treatment of resected colon cancer. 2016 Gastrointestinal Cancers Symposium, Abstract
2. J. Deluce, D. Maj, G. Boldt, D. Breadner, J. Raphael. Efficacy and toxicity of combined inhibition of EGFR and VEGFR in advanced non-small cell lung cancer patients harboring activating EGFR mutations: A systematic review and meta-analysis. ESMO Annual Congress, Madrid, Spain
Conference Date: 2020/9
Poster
Refereed?: Yes
3. Breadner, D. , Vincent , M., Correa, R. , Black, M. , Warner, A. , Qu, M. , Logan, D. , Sanatani, M. , Younus, J. , Yaremko, B. , Rodrigues, G. , Blanchette, P. , Bhat, V. , Morris, C. , Green, E. , Jones, G. , Allan, A. , Palma, D. , Raphael, J. Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: a first-in-human pilot study. American Society of Clinical Oncology Annual Meeting, Chicago, United States of America
Conference Date: 2020/6
Poster
Refereed?: Yes
4. Lakkunarajah, S., Breadner, D. Zhang, H., Spratlin, J.L., Mulder, K.E., Gill, S., Sha, A., Abadi, S., Kong, S., Cheung, W.Y., Loree, J.M., Welch, S. The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: A multicenter retrospective analysis. Gastrointestinal Cancer Symposium, San Francisco, United States of America
Conference Date: 2020/1
Poster
Refereed?: Yes
5. Surujballi, J., Breadner, D., Morris, D., O'Connor, A., Whiston, F., Stitt, L., Vincent, M.D. A Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer. World Conference on Lung Cancer, Toronto, Canada
Conference Date: 2019/9
Poster
Refereed?: Yes
6. Liu, R., Patel, S.V.B., Garcia-Ochoa, C., Breadner, D., Welch, S., Skaro, A., Leslie, K. Impact of Adjuvant Chemotherapy Completion Rates on Outcomes Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Americas Hepato-Pancreato-Biliary 2019 Annual Meeting, Miami Beach, United States of America
Conference Date: 2019/3
Poster
Refereed?: Yes
7. Mahler M, Zhang Y, Hueniken K, Brown MC, Chen Z, Mirshams M, Wang J, Siu LL, Spreafico A, Breadner D, Teft, WA, Winquist E, Liu G. Cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation: The role of WFS1 and ABCC2 heritable variants. 2018 ASCO Annual Meeting I,
Conference Date: 2018/6
Abstract

8. Mahler, M., Zhang, Y., Hueniken, K., Brown, M.C., Chen, Z., Mirshams, M., Wang, J., Siu, L.L., Spreafico, A., Breadner, D.A. and Teft, W.A., Winkquest, E., Liu, G. Cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation: The role of WFS1 and ABCC2 heritable variants. ASCO Annual Meeting, Chicago, United States of America
Conference Date: 2018/5
Poster
Refereed?: Yes
9. Mahler, M., Teft, W., Breadner, D., Bukhari, N., Kuruvilla, S., Nichols, A., Palma, D., Kim, R., Winkquest, E. The effect of MATE1 polymorphisms on cisplatin efficacy in the treatment of head and neck cancer. Head and Neck Cancer Symposium, Scottsdale, United States of America
Conference Date: 2018/1
Poster
Refereed?: Yes

Presentations

1. (2024). Updates in the systemic treatment of biliary tract cancers. GI Disease Site Team Meeting, Canada
Main Audience: Knowledge User
Invited?: No, Keynote?: No
2. (2023). Ask the Expert: Tough Questions in First-line upper gastrointestinal cancers. Bristol-Myers-Squibb, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
3. (2022). Better Breathing Conference - Updates in Treatment of Metastatic Lung Cancer. The Lung Health Foundation, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
4. (2022). Updates in Extensive Stage Small Cell Lung Cancer. Oncology Education, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
5. (2020). Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. Canadian Association of Medical Oncologists Annual Meeting, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No

Date Submitted: 2024-09-30 22:45:03

Confirmation Number: 1836088

Template: Full CV

Dr. SAQIB RAZA KHAN

Correspondence language: English

Sex: Male

Date of Birth: 1/31

Canadian Residency Status: Student Work Permit

Country of Citizenship: Pakistan

Contact Information

The primary information is denoted by (*)

Address

Mailing (*)

Dorinda Street 445

Dorinda Street 445

London Ontario N5W 4B3

Canada

Telephone

Mobile (*)

+1-519-2263858867

Email

Work (*)

saqib.khan@lhsc.on.ca

Dr. SAQIB KHAN**Language Skills**

Language	Read	Write	Speak	Understand	Peer Review
English	Yes	Yes	Yes	Yes	Yes

Degrees

2024/7 (2026/6)	Certificate, Clinical Fellowship, Medical Oncology, University of Western Ontario Degree Status: In Progress Thesis Title: NA
2017/1 - 2021/12	Post-doctorate, FCPS, Medical Oncology, Aga Khan University Degree Status: Completed Thesis Title: Recurrence free survival and pattern of recurrence in pancreatic ductal adenocarcinoma
2021/9 - 2021/9	Post-doctorate, Specialty Certificate Examination of Medical Oncology, Medical Oncology, Royal College of Physicians Degree Status: Completed Thesis Title: NA
2008/9 - 2014/3	Bachelor's, MBBS, Medicine and Surgery, Dow University of Health and Sciences Degree Status: Completed Thesis Title: NA

Credentials

2024/7	Clinical Fellow, University of Western Ontario
--------	--

Recognitions

2024/6 - 2024/6	Award of Appreciation Aga Khan University Honor
2024/2 - 2024/2	ESMO Advanced Course on Early Drug Development - 600 (Euro) European Society of Medical Oncology Prize / Award
2023/12 - 2023/12	ESMO Advanced Course on Locoregional and Systemic Therapy in Advanced HCC Patients - 600 (Euro) European Society of Medical Oncology Prize / Award

2022/12 - 2022/12	National Burki Gold Medal College of Physicians and Surgeons Pakistan Honor Burki Gold Medal Award is given to the outstanding candidate by CPSP, who scored highest among all specialties for the given academic year. It was given to me for the year 2022.
2022/10 - 2022/10	ESMO Advanced Course on Biomarkers for Precision Medicine - 600 (Euro) European Society of Medical Oncology Prize / Award
2021/12 - 2021/12	Best Resident of the Year Aga Khan University Honor Given as the best resident of the year-2021 by the dean of my university hospital.

User Profile

Researcher Status: Post-doctoral Student

Research Career Start Date: 2017/01/01

Engaged in Clinical Research?: Yes

Key Theory / Methodology: Experienced in evidence-based clinical research in oncology, focusing on the clinical impact of interventions and outcomes.

Research Interests: Thoracic Oncology with a focus on NSCLC and Upper GI. Circulating tumor DNA, molecular and genetics Nutritional Interventions in Oncology

Research Specialization Keywords: Lung Cancer, Upper GI, Circulating Tumor DNA, Molecular Biology

Geographical Regions: Central Canada

Countries: Pakistan, Canada

Employment

2024/7 - 2026/6	Clinical Fellow Medical Oncology, London Regional Cancer Program, University of Western Ontario Full-time, Term
2023/10 - 2024/6	Chair of Morbidity and Mortality meeting (M&M) Aga Khan University
2023/6 - 2024/6	Co-chair of Entrustable Professional Activities (EPA) developmental program Aga Khan University Full-time I acted as a co chair of the EPA clinical competency committee and was responsible for the development and implications of EPA in the Department of Medical Oncology at AKUH.
2023/3 - 2024/6	Elective Program Coordinator Aga Khan University Responsible for elective students application process for undergraduate students.
2022/10 - 2024/6	Senior Instructor Medical Oncology, AKUH campus, Aga Khan University Full-time, Consultation Worked as a full time faculty in the department of medical oncology.

2017/1 - 2021/12	Resident Medical Oncology, AKUH Campus, Aga Khan University Full-time, Term Trainee resident in the disciplines of medicine and oncology.
2014/6 - 2015/5	Internship Medicine and Surgery, Sindh Medical College, Jinnah Postgraduate Medical Center Full-time, Term

Affiliations

The primary affiliation is denoted by (*)

(*) 2024/7 Clinical Fellow, University of Western Ontario

Courses Taught

2024/09/24 - 2024/10/24	Mentor, University of Western Ontario Course Title: Lung Cancer Number of Students: 1
2022/10/22 - 2024/05/31	Curriculum Developer, Aga Khan University Course Title: Curriculum Developer for Medical Oncology Trainee Residents Number of Students: 10
2024/01/01 - 2024/03/31	Tutor, Aga Khan University Course Title: Gastrointestinal Malignancies Section: Medical Oncology Number of Students: 13 Lecture Hours Per Week: 1
2023/05/01 - 2023/07/31	Tutor, Aga Khan University Course Title: Lung Cancer Module Course Level: Post Graduate Section: Medical Oncology Number of Students: 13 Lecture Hours Per Week: 1
2022/11/01 - 2023/04/30	Mentor, Aga Khan University Course Title: Lung Cancer Course Topic: Advanced Lung Cancer Number of Students: 5 Lecture Hours Per Week: 1
2021/09/21 - 2021/09/26	Workshop Facilitator, Aga Khan University Course Title: Tumor Board Saves Lives Number of Students: 35

Course Development

2023/11	Course Development, Aga Khan University Course Title: Entrustable Professional Activity Course Level: Post Graduate I was responsible for the development and implications of EPA in the Department of Medical Oncology at AKUH
---------	--

Student/Postdoctoral Supervision

Master's Thesis [n=1]

2023/2 - 2024/12 Kiran Sarfaraz (In Progress) , Aga Khan University Hospital
 Co-Supervisor Degree Name: BSN
 Student Degree Start Date: 2023/1
 Student Canadian Residency Status: Not Applicable
 Thesis/Project Title: Clinical Learning and Mnaagement
 Present Position: Staff Nurse, Aga Khan University

Event Administration

2021/9 - 2021/9 Event Management, PGME Silver Jubilee, Workshop, Aga Khan University Hospital

Conference Review Activities

2024/4 - 2024/4 Organizer Committee Member, Annual Research Conference, Blind, Aga Khan University Hospital
 2024/2 - 2024/2 Organizer Committee Member, National Health Sciences Research Symposium, Blind, Aga Khan University Hospital
 Number of Works Reviewed / Refereed: 10

Graduate Examination Activities

Committee Member, Aga Khan University

Other Memberships

Member, European Society for Medical Oncology
 Member, Society of Medical Oncology of Pakistan
 Member, Canadian Association of Medical Oncologist
 Member, American Society of Clinical Oncology

Presentations

1. (2023). Clinical outcomes of using Abiraterone in advanced Prostate cancer Management. Beacon International Cancer Summit, Algeria
 Main Audience: Knowledge User
 Invited?: Yes, Keynote?: Yes, Competitive?: No
2. (2023). Chemotherapy-induced Febrile Neutropenia. CME conference, Azerbaijan
 Main Audience: Knowledge User
 Invited?: Yes, Keynote?: Yes, Competitive?: No

3. (2022). Outcomes of Patients in Nodal vs Extranodal Diffuse Large B-cell Lymphoma: An Institutional Perspective. JAPAN SOCIETY OF CLINICAL ONCOLOGY, Japan
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No, Competitive?: Yes
4. (2021). Management of CML in exceptional Circumstances. Society of Medical Oncology Pakistan, Pakistan
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No, Competitive?: No
5. (2021). Lenalidomide induces secondary B-cell Acute Lymphoblastic Leukemia (B-cell ALL) in Multiple Myeloma Patient. American Society of Hematology, United States of America
Main Audience: Knowledge User
Invited?: No, Keynote?: No, Competitive?: Yes
6. (2021). Management of metastatic colorectal cancer. Gastrointestinal Symposium, Pakistan
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No, Competitive?: No

Publications

Journal Articles

1. Soomro MY, Khan SR, Ishfaq H, Ali I, Samar MR, Hameed A, Zehra N, Moosajee M, Rashid YA. (2024). Clinical outcomes in metastatic prostate adenocarcinoma treated with abiraterone and enzalutamide. *ecancer medical science*. 18(9): 763.
<http://dx.doi.org/https://doi.org/10.3332/ecancer.2024.1763>
Co-Author
Published,
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 9
Description of Contribution Role: Corresponding author and supervisor
2. Dawood T, Rashid YA, Khan SR, Jabbar AA, Zahir MN, Moosajee MS. (2024). Outcomes of locally advanced gastric and gastroesophageal adenocarcinoma cancers treated with neoadjuvant FLOT in a tertiary care hospital in Pakistan. *ecancer medical science*. 18(5): 1705.
<http://dx.doi.org/https://doi.org/10.3332/ecancer.2024.1705>
Co-Author
Published, , Open Access?: Yes, Synthesis?: No
Description of Contribution Role: Corresponding author
3. Saeed N, Khan ZF, Jehanzeb H, Irshad HA, Shaikh U, Adil SN, Shaikh T, Ashfaq D, Jahangir F, Khan SR, Zehra N. (2024). Frequency of Deletion 13q14. 3 and Its Impact on Outcome in Patients of Chronic Lymphocytic Leukemia; A Single-Centered Institutional Study from Pakistan. *Journal of Haematology and Stem Cell Research*. 4(1): 120-124.
Co-Author
Published,
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 11
4. KHAN SR, HAQUE S, FAGOONEE S, AHMAD F, RAZA A. (2024). Precision oncology, cutting the edge: a need for developing cost-based global guidelines for circulating tumor DNA testing in the climate/era of economic uncertainty. *Minerva Biotechnology & Biomolecular Research*. 36(2): 103.
<http://dx.doi.org/10.23736/s2724-542X.24.03136-5>
First Listed Author
Published, , Open Access?: No, Synthesis?: No
Number of Contributors: 5

5. Soomro MY, Khan SR, Muhammad H, Ahmad S, Zehra N, Ali I, Samar MR, Hameed A, Moosajee M, Rashid YA. (2024). Exploring treatment outcomes in Stage II-III rectal cancer patients undergoing neoadjuvant therapy at a tertiary care center in Pakistan: a comprehensive analysis of pathological outcomes. BMC cancer. 24(1): 479.
Co-Author
Published,
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 10
Description of Contribution Role: Corresponding author and supervisor
6. Shahzadi M, Khan SR, Tariq M, Baloch SS, Shahid A, Moosajee M, Samon Z. (2023). Review of current literature on gestational trophoblastic neoplasia. Journal of the Egyptian National Cancer Institute. 35(1): 37.
<http://dx.doi.org/https://doi.org/10.1186/s43046-023-00195-y>
Co-Author
Published,
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 7
Description of Contribution Role: Corresponding author
7. Khan SR, Scheffler M, Soomar SM, Rashid YA, Moosajee M, Ahmad A, Raza A, Uddin S. (2023). Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker. Pathology-Research and Practice. 245(5): 154455.
<http://dx.doi.org/https://doi.org/10.1016/j.prp.2023.154455>
First Listed Author
Published,
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 8
8. Baloch SS, Khan SR, Tariq M, Wasio A, Ali AA, Shahzadi M, Moosajee M, Anwar S, Raza A, Uddin S. (2023). Multiple myeloma and its rare paraneoplastic manifestations simmering under the surface. Pathology-Research and Practice. 15(7): 154689.
<http://dx.doi.org/https://doi.org/10.1016/j.prp.2023.154689>
Co-Author
Published,
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 10
9. Khan SR, Soomar SM, Asghari T, Ahmed A, Moosajee MS. (2023). Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years' clinical experience from a tertiary care center in Pakistan. BMC Cancer. 23(1): 510.
<http://dx.doi.org/https://doi.org/10.1186/s12885-023-11000-3>
First Listed Author
Published,
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 5
10. Samar MR, Merchant S, Zehra NE, Idrees R, Khan SR. (2023). Thin on the ground: Primary mucosal melanoma of the nasal cavity. International Journal of Surgery Case Reports. 111(10): 108929.
<http://dx.doi.org/https://doi.org/10.1016/j.ijscr.2023.108929>
Co-Author
Published,
Refereed?: Yes, Open Access?: Yes, Synthesis?: No
Number of Contributors: 5
Description of Contribution Role: Writing, Editing and Supervision of the manuscript

11. Khan SR, Shoaib D, Soomar SM, Afzal M, Sidhu SM, Tariq M, Zahir MN, Moosajee M, Jabbar AA, Rashid YA. (2023). Mean level of pretreatment neutrophil to lymphocyte ratio in patients with squamous cell carcinoma of the head and neck–Cross-sectional study.Heliyon. 9(5): 15894.
<http://dx.doi.org/https://doi.org/10.1016/j.heliyon.2023.e15894>
 First Listed Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 10

12. Ahmed F, Khan SR, Dawood T, Naeem A, Moosajee M, Rashid YA. (2023). Chaotic transformation of parotid acinic cell carcinoma to metastatic dedifferentiated high-grade pathology-A rare case with clinical and emotional challenge.International Journal of Surgery Case Reports.110(9): 108784.
<http://dx.doi.org/https://doi.org/10.1016/j.ijscr.2023.108784>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 6
 Description of Contribution Role: Corresponding Author

13. Khan SR, Nasir S, Tariq M, Rashid YA, Jabbar AA. (2022). Cardiac sarcoma: A rare case of primary cardiac sarcoma.International Journal of Surgery Case Reports. 102(1): 107836.
<http://dx.doi.org/https://doi.org/10.1016/j.ijscr.2022.107836>
 First Listed Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 5

14. Khan SR, Nasir S, Zahir MN, Rashid YA. (2022). Trick or Treat: Curative Management of Esophageal Squamous Cell Carcinoma of a COVID-positive Patient.Advances in Bioscience and Clinical Medicine.10(4): 9-12.
<http://dx.doi.org/https://doi.org/10.7575/aiac.abcm.v.10n.4p.9>
 First Listed Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 4

15. Khan SR, Muhammad A, Soomar SM, Shoaib D, Ali AA, Muhammad T, Zahir MN, Jabbar AA, Rashid YA, Heger M, Moosajee MS. (2022). No difference in treatment outcome between patients with nodal versus extranodal diffuse large B-cell lymphoma.Journal of clinical and translational research.9(1): 37.
<http://dx.doi.org/http://dx.doi.org/10.18053/jctres.09.202301.005>
 First Listed Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 11

16. Khan SR, Tariq M, Fayyaz SM, Soomar SM, Moosajee M. (2022). Lenalidomide induced secondary acute lymphoblastic leukemia in a multiple myeloma patient. Leukemia research reports.17(1): 100315.
<http://dx.doi.org/https://doi.org/10.1016/j.lrr.2022.100315>
 First Listed Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 5

17. Samar MR, Khan SR, Tariq M, Soomar SM, Shahzadi M. (2022). Bilateral congenital cryptorchidism and unilateral Leydig cell tumor in an adult presenting with gynecomastia and primary infertility. *International Journal of Surgery case reports*.93(4): 106923.
<http://dx.doi.org/https://doi.org/10.1016/j.ijscr.2022.106923>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 5
 Description of Contribution Role: Corresponding author
18. Tariq M, Baloch SS, Khan SR, Shahzadi M, Khan MD, Zahid MJ, Shah SJ, Rashid YA. (2022). Efficacy of Furosemide in Methotrexate Clearance in Patients Treated with High Dose Methotrexate. *Pakistan Journal of Medical & Health Sciences*.16(4): 485-487.
<http://dx.doi.org/https://doi.org/10.53350/pjmhs22164485>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 10
19. Tariq M, Ibrahim M, Khan SR, Baloch SS, Shahzadi M, Rashid YA, Zahid MJ, Khan MD. (2022). Frequency of Cardiac-Toxicity in Patient Treated with Anthracycline, An Institutional Perspective. *Pakistan Journal of Medical & Health Sciences*.6(4): 488-490.
<http://dx.doi.org/https://doi.org/10.53350/pjmhs22164498>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 8
20. Tariq M, Khan SR, Rashid YA, Zahir MN, Jabbar AA, Moosajee M, Shah SJ, Baloch SS, Soomar S. (2022). Recurrence free survival and patterns of recurrence in squamous cell carcinoma of oral cavity: An institutional perspective. *Journal of Postgraduate Medical Institute*. 36(4): 236-239.
<http://dx.doi.org/https://doi.org/10.54079/jpmi.36.4.3028>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 9
21. Nasir S, Khan SR, Iqbal R, Hashmi AP, Moosajee M, Nasir N. (2022). Inactivated COVID-19 vaccine triggering hemophagocytic lymphohistiocytosis in an immunocompetent adult. *Journal of clinical and translational research*. 8(2): 152-155.
<http://dx.doi.org/http://dx.doi.org/10.18053/jctres.08.202202.009>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 6
22. Shoaib D, Khan SR, Rashid YA, Zahir MN. (2022). Abdominal myoepithelial carcinoma: A rare abdominal wall entity of an uncommon tumor. *International Journal of Surgery Case Reports*.99(10): 107618.
<http://dx.doi.org/https://doi.org/10.1016/j.ijscr.2022.107618>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 4
 Description of Contribution Role: Corresponding author

23. Tariq M, Baloch SS, Khan SR, Shahzadi M, Khan MD, Zahid MJ, Shah SJ, Rashid YA. (2022). Influence of Cancer News on Quality of Life of Patients Families: An Observational Study. *Pakistan Journal of Medical & Health Sciences*.16(4): 495-497.
<http://dx.doi.org/https://doi.org/10.53350/pjmhs22164495>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 8
24. Khan SR, Nasir S, Tariq M, Siddiqui ZA, Moosajee M. (2021). Primary central nervous system T-cell lymphoma associated with hepatitis B and D virus coinfection. *Cureus*.13(4): 14394.
<http://dx.doi.org/https://doi.org/10.7759%2Fcureus.14394>
 First Listed Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 5
25. Shoaib D, Zahir MN, Khan SR, Jabbar AA, Rashid YA. (2021). Difficulty breathing or just a case of the nerves? Incidental finding of primary pleural schwannoma in a COVID-19 survivor. *Cureus*.13(8): 17511.
<http://dx.doi.org/https://doi.org/10.7759%2Fcureus.17511>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 5
 Description of Contribution Role: Corresponding author
26. Farooqi H, Patel H, Aslam HM, Ansari IQ, Khan M, Iqbal N, Rasheed H, Jabbar Q, Khan SR, Khalid B, Nadeem A. (2013). Effect of Facebook on the life of Medical University students. *International archives of medicine*. 6(1): 1-8.
<http://dx.doi.org/https://doi.org/10.1186/1755-7682-6-40>
 Co-Author
 Published,
 Refereed?: Yes, Open Access?: Yes, Synthesis?: No
 Number of Contributors: 11

Conference Publications

1. Khan S, Muhammad T, Rashid YA. (2022). EFFICACY OF FUROSEMIDE IN METHOTREXATE CLEARANCE IN PATIENTS TREATED WITH HIGH DOSE METHOTREXATE. *Hematology, Transfusion and Cell Therapy*. XIIth Eurasian Hematology-Oncology Congress, istanbul, Turkey (34),
<http://dx.doi.org/https://doi.org/10.1016/j.htct.2022.09.1251>
 Conference Date: 2022/10
 Abstract
 First Listed Author
 Published
 Refereed?: No, Invited?: Yes
 Number of Contributors: 3

2. Khan S, Muhammad T, Rashid YA. (2022). INFLUENCE OF CANCER NEWS ON QUALITY OF LIFE OF PATIENT'S FAMILIES: AN OBSERVATIONAL STUDY. Hematology, Transfusion and Cell Therapy. XIIth Eurasian Hematology-Oncology Congress, istanbul, Turkey (26),
<http://dx.doi.org/https://doi.org/10.1016/j.htct.2022.09.1234>
Conference Date: 2022/10
Abstract
First Listed Author
Published
Refereed?: No, Invited?: Yes
Number of Contributors: 3